Uploaded January 2013 | Updated September 2026, 2 hours ago
Presented at the 13th Clinical Applications for Age Management Medicine, November 2012, Las Vegas, NV
H. Robert Superko, M.D., FACC, FAHA, FACC
Clinical Professor, Mercer University School of Pharmaceutical Sciences, Atlanta, GA
Chief of Medical Affairs, Celera Corporation, Alameda, CA
Lecture Description:
Cardiovascular disease remains the leading cause of morbidity and mortality in the USA. The approximate 25% relative risk reduction consistently reported in clinical trials achieving LDL-C reduction with statin medications is actually only a 3% absolute risk reduction. There is a need to go beyond standard risk factors to diagnose the potential etiology in individual patients, and to create the most successful individual therapeutic approach. Genetic cardiology has exploded in the past decade and tests currently exist that independently predict CVD events in both primary and secondary prevention, guide individualized therapy, and assist in identification of first degree relatives at very high risk for CVD events. Practical, specific disorders and response to treatment will be identified and case studies presented.
The Age Management Medicine Group (AMMG) provides education and information on the specialty of Age Management Medicine through evidence-based continuing medical education conferences, workshops, seminars, certifications, publications and web media.
Website at agemed.org
Presented at the 13th Clinical Applications for Age Management Medicine, November 2012, Las Vegas, NV
H. Robert Superko, M.D., FACC, FAHA, FACC
Clinical Professor, Mercer University School of Pharmaceutical Sciences, Atlanta, GA
Chief of Medical Affairs, Celera Corporation, Alameda, CA
Lecture Description:
Cardiovascular disease remains the leading cause of morbidity and mortality in the USA. The approximate 25% relative risk reduction consistently reported in clinical trials achieving LDL-C reduction with statin medications is actually only a 3% absolute risk reduction. There is a need to go beyond standard risk factors to diagnose the potential etiology in individual patients, and to create the most successful individual therapeutic approach. Genetic cardiology has exploded in the past decade and tests currently exist that independently predict CVD events in both primary and secondary prevention, guide individualized therapy, and assist in identification of first degree relatives at very high risk for CVD events. Practical, specific disorders and response to treatment will be identified and case studies presented.
The Age Management Medicine Group (AMMG) provides education and information on the specialty of Age Management Medicine through evidence-based continuing medical education conferences, workshops, seminars, certifications, publications and web media.
Website at agemed.org
